Coalition for Epidemic Preparedness Innovations

What Coalition for Epidemic Preparedness Innovations does

The Coalition for Epidemic Preparedness Innovations (CEPI) is a global non-profit partnership founded in 2017 in response to the 2014-2016 West Africa Ebola epidemic, headquartered in Oslo with offices in London and Washington D.C. and ~340 employees from 60+ countries. CEPI funds and coordinates vaccine and biologic countermeasure development against epidemic and pandemic threats across multiple technology platforms (mRNA, viral vectors including VSV and ChAdOx1, recombinant proteins, nanoparticle approaches), supporting 75+ vaccine candidates and partnering with 470+ R&D and manufacturing organizations. Its go-to-market is community-led: CEPI issues public Calls for Proposals, deploys donor funding as grants to vaccine developers, and operates a Vaccine Manufacturing Facility Network to position global manufacturing capacity for rapid outbreak response, with equitable access obligations embedded in every funding agreement.

CEPI's revenue model is grant and donor funding from 30+ government, philanthropic, and private sector investors; it does not sell products. Up to $3.6 billion has been committed since 2017, with CEPI 3.0 (2027-2031) targeting $2.5 billion. Beyond direct R&D funding, CEPI is building two technology platforms: the Pandemic Preparedness Engine (PPX), an AI-driven digital platform with agentic capabilities for coordinating pathogen surveillance, vaccine design, and regulatory workflows (built with a biosecurity-by-design framework in collaboration with Sentinel Bio and RAND), and participation in OpenAI's Rosalind Biodefense program for frontier AI biosecurity tooling. The organization's primary customers/beneficiaries are global governments and health agencies (WHO, Africa CDC, Gavi, UNICEF, PAHO), LMIC populations facing endemic and outbreak threats, and vaccine developers receiving CEPI funding. CEPI co-led the COVAX facility, which shipped nearly 2 billion COVID-19 vaccine doses to 146 countries and is estimated to have averted 2.7 million deaths by end of 2022.

Name

Coalition for Epidemic Preparedness Innovations

Legal name

The Coalition for Epidemic Preparedness Innovations

Website

https://cepi.net

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

251–500 employees

Short description

CEPI is a global non-profit partnership founded in 2017 that funds and coordinates vaccine and biologic countermeasure development against epidemic and pandemic threats, serving governments, health agencies (WHO, Africa CDC, Gavi, UNICEF), and LMIC populations through a 470+ partner R&D and manufacturing network.

Ownership category

akta.pro rank

Product category

Global Health / Pandemic Preparedness

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF)

Keywords

• Epidemic preparedness
• Vaccine development
• Pandemic response
• Global health security
• Biologic countermeasures

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Grant and donor funding: CEPI is funded by governments, philanthropies, and private donors. It deploys this funding as grants to vaccine developers. Revenue is not generated from product sales; CEPI is a non-profit partnership.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

CEPI is a global partnership that funds and coordinates the development of vaccines and other biologic countermeasures against epidemic and pandemic threats. It provides grants and push/pull financing to vaccine developers worldwide, manages a portfolio of 75+ vaccine candidates across multiple technology platforms, operates a Vaccine Manufacturing Facility Network for rapid outbreak response, and is building the AI-driven Pandemic Preparedness Engine (PPX) to compress vaccine development timelines toward its 100 Days Mission.

Product overview

CEPI operates as a vaccine development coalition offering a portfolio of interconnected programs and AI-powered platforms rather than a traditional software product. The core offering is the PPX (Pandemic Preparedness Engine), an AI-powered platform that coordinates vaccine development workflows across surveillance, design, clinical development, and manufacturing. This platform integrates with GPT-Rosalind, a generative AI tool developed with OpenAI, to enable biosecurity applications. CEPI's vaccine development programs and the 100 Days Mission initiative provide the programmatic framework within which these technology tools operate.

Differentiator

Problem solved

Functional benefit

Products and services

• Pandemic Preparedness Engine (PPX) An AI-powered digital platform under development that integrates pathogen surveillance data, vaccine design research, clinical development, regulatory pathways, and manufacturing networks to accelerate vaccine development during epidemic and pandemic threats. It uses a tiered managed-access framework with multiple biosecurity layers including cybersecurity, federated data architecture, risk assessments, and an autonomous biosecurity monitoring agent.
• GPT-Rosalind Biosecurity AI A generative AI system developed in partnership with OpenAI, designed to bolster global health security through biosecurity applications, literature review, and threat assessment capabilities for vetted government and public health partners including CEPI.
• 100 Days Mission A global initiative to compress vaccine development timelines to 100 days in response to a novel pathogen outbreak, coordinating funding, research networks, regulatory alignment, and manufacturing capacity across international partners and embraced by G7 and G20 leaders.
• Vaccine Development Programs (Priority Pathogen Portfolio) CEPI-funded vaccine development programmes covering priority pathogens including Chikungunya, Coronaviruses, Disease X, Filoviruses (Bundibugyo Ebola, Zaire Ebola), Lassa Fever, Mpox, Nipah, Rift Valley Fever, and H5N1/H5 pandemic influenza, delivered through grant funding and partnerships with biotech firms, academic institutions, and manufacturers.
• Vaccine Manufacturing Facility Network (VMFN) A global network of vaccine manufacturing partners (including Serum Institute of India, Samsung Biologics, Bio Farma, Institut Pasteur de Dakar, Afrigen, and Fiocruz) positioned to rapidly produce vaccine doses during outbreaks for Low- and Middle-Income Countries.
• COVAX Facility CEPI co-created and co-led COVAX alongside Gavi, UNICEF, and WHO to accelerate development, manufacturing, and equitable distribution of COVID-19 vaccines, shipping nearly 2 billion doses to 146 countries.

Quantifiable outcome

• COVAX shipped nearly 2 billion COVID-19 vaccine doses to 146 countries, averting an estimated 2.7 million deaths by end of 2022.
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature3 records

Partnerships

19 partnerships are on record, tiered core, minor and important.

• Public Health Vaccines (PHV)coreStrategic or Co-development Partner · 9 June 2026CEPI awarded $1.9 million to Public Health Vaccines to rapidly advance its rVSV-based Bundibugyo vaccine candidate into clinical testing by generating Master Viral Seed stock. PHV has committed to enabling rapid, affordable supply of a successful Bundibugyo vaccine to affected countries.
• Soligenix / University of Hawaiʻi at MānoaminorStrategic or Co-development Partner · 8 June 2026Soligenix applied for CEPI funding to develop a thermostable protein-based subunit vaccine for Bundibugyo Ebola using its ThermoVax platform in collaboration with Dr. Axel Lehrer at the University of Hawaiʻi at Mānoa, which demonstrated up to 100% protection in non-human primates against related filoviruses.
• POP Bio (POP Biotechnologies)importantStrategic or Co-development Partner · 3 June 2026CEPI provided up to $9.7 million to advance POP Bio's SNAP nanoparticle vaccine platform into Phase 1 clinical trials, with an H5N1 influenza candidate as the validation target. The platform uses cobalt-modified porphyrin-phospholipid liposomes enabling 30-minute antigen purification.
• ModernacoreStrategic or Co-development Partner · 1 June 2026CEPI committed up to $50 million to Moderna for preclinical testing and Phase 1 clinical trials of an mRNA Bundibugyo ebolavirus vaccine candidate. CEPI will support simultaneous manufacturing of doses to enable large-scale Phase 2/3 trials to begin immediately if Phase 1 data supports progression. The collaboration builds on CEPI's existing strategic partnership with Moderna.
• International AIDS Vaccine Initiative (IAVI)coreStrategic or Co-development Partner · 1 June 2026CEPI committed up to $3.2 million to IAVI for preparations to generate Master Virus Seed stock and initiate testing of an rVSV-based Bundibugyo vaccine candidate using the same platform as the licensed Zaire Ebola vaccine. This candidate was identified by WHO as the most promising.
• University of Oxford / Serum Institute of IndiacoreStrategic or Co-development Partner · 1 June 2026CEPI committed up to $8.6 million to University of Oxford (with SII manufacturing) for ChAdOx1-based Bundibugyo vaccine preclinical development, Master Virus Seed stock creation, and manufacturing of clinical-grade doses. Leverages Oxford's existing ChAdOx1 platform (Oxford/AstraZeneca COVID-19 vaccine).
• OpenAI — Rosalind BiodefenseimportantTechnology or Integration · 29 May 2026OpenAI's Rosalind Biodefense program provides frontier AI tools (GPT-Rosalind model) to vetted government and public health partners including CEPI for pandemic preparedness and biosecurity applications, including vaccine development workflows for the Bundibugyo Ebola outbreak.
• PAHOimportantStrategic or Co-development Partner · 21 April 2026CEPI and PAHO expanded their partnership to strengthen regulatory systems and vaccine safety across the Americas, supporting regional vaccine R&D and outbreak preparedness.
• Pasteur NetworkimportantStrategic or Co-development Partner · 21 April 2026CEPI and the Pasteur Network partnered to advance regional vaccine R&D and outbreak preparedness, leveraging the Network's established research infrastructure across Francophone Africa and beyond.
• WHO South-East Asia Regional Office (SEARO)minorStrategic or Co-development Partner · 14 April 2026WHO SEARO and CEPI co-convened a three-day Regional Consultation on Vaccine and Immunization Research Preparedness in New Delhi, India, with 90+ participants to advance the 100 Days Mission across the South-East Asia Region.
• Republic of KoreaminorStrategic or Co-development Partner · 5 February 2026The Republic of Korea, in partnership with CEPI and IVI, hosted a landmark two-day pandemic simulation exercise in Seoul to strengthen readiness for rapid vaccine development and support the 100 Days Mission.
• German Center for Infection Research (DZIF)minorStrategic or Co-development Partner · 26 January 2026DZIF and CEPI co-funded a Phase I clinical trial showing MVA-MERS-S vaccine candidate induces stable functional immune response persisting at least 24 months, demonstrating durable immunity against MERS.
• CognizantminorImplementation/ SI/ Consulting Partner · 20 November 2025Cognizant was selected by CEPI to lead a digital transformation initiative implementing a new HR and Expense Management System and consolidating CEPI's Salesforce platform, enhancing organizational efficiency through platform modernization and automation.
• Serum Institute of India (SII) — NipahimportantStrategic or Co-development Partner · 30 October 2025SII partnered with University of Oxford and CEPI to produce a Nipah virus vaccine candidate with $7.3M funding, aiming to create an investigational reserve of up to 100,000 doses for emergency use. This marks the world's first Phase II Nipah virus vaccine trial.
• Serum Institute of India (SII) — Disease XimportantStrategic or Co-development Partner · 19 October 2025CEPI and SII are collaborating to develop and test vaccines for Disease X using a baculovirus platform with funding of up to $16.4 million, simulating rapid response capabilities for future pandemics with potential vaccine availability within 100 days.
• Afrigen — mRNA partnershipcoreTechnology or Integration · 27 August 2024CEPI partnered with Afrigen to speed up mRNA vaccine development and access, leveraging Afrigen's end-to-end mRNA production capabilities and technology transfer network across Africa.
• World Health Organization (WHO)coreStrategic or Co-development PartnerWHO coordinates global outbreak response and is a key CEPI partner for regulatory alignment, outbreak scenario modelling, clinical trial design, and Emergency Use Listing of CEPI-funded vaccines.
• Africa CDCcoreStrategic or Co-development PartnerAfrica CDC leads the continental public health emergency response and is a key partner in CEPI's outbreak coordination, regulatory alignment, and equitable access framework for African populations.
• SK bioscienceminorStrategic or Co-development PartnerSK bioscience filed for a first-in-human Phase 1/2 trial of GBP511, a Universal Coronavirus (Pan-sarbecovirus) vaccine, as part of broader efforts to improve pandemic preparedness supported by CEPI's ecosystem.

Scale indicators17 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• DNDi (Drugs for Neglected Diseases initiative): DNDi is a non-profit product development partnership focused on treatments for neglected diseases. It mirrors CEPI's model of coordinating R&D across public, private and philanthropic partners for markets with limited commercial incentive — though DNDi focuses on therapeutics rather than vaccines.
• Wellcome Trust: Wellcome is a major UK-based global health funder that supports vaccine R&D and epidemic preparedness. It is comparable to CEPI in mission scope but funds through grants to academic and biotech researchers rather than operating a portfolio coalition model.

Regional players

• Africa CDC: Africa CDC coordinates continental public health emergency response and is a key CEPI partner on outbreak coordination, regulatory alignment and equitable access in Africa. It is regionally focused where CEPI is global, and increasingly competes for African vaccine R&D and manufacturing investments.
• European Health Emergency Preparedness and Response Authority (HERA): HERA is the EU's dedicated health emergency preparedness agency, established in 2021 with multi-billion-euro budgets for vaccines, therapeutics and diagnostics. It is a regional counterpart to CEPI that competes for mandate and partners within Europe.

Broad incumbents

• BARDA (Biomedical Advanced Research and Development Authority): BARDA is the US government's primary agency funding advanced vaccine and biodefense R&D. It co-funds CEPI's Bundibugyo portfolio alongside Moderna and serves as a national-level counterpart to CEPI's international mandate.
• Bill & Melinda Gates Foundation: The Gates Foundation is a major global health funder that co-finances vaccine R&D, manufacturing capacity (including Afrigen) and pandemic preparedness initiatives. It overlaps with CEPI on funding priorities and on several shared grantees in LMIC manufacturing.
• World Health Organization (WHO): WHO is the broad incumbent in global health that CEPI partners with for outbreak coordination, regulatory alignment (Emergency Use Listing) and scenario modelling. WHO sets norms across all global health, while CEPI is a specialized vaccine R&D funder within that ecosystem.

Direct peers

• Gavi, the Vaccine Alliance: Gavi is CEPI's closest peer — both are global vaccine alliances pooling public and philanthropic capital to accelerate access. Gavi focuses on procurement and pull financing (notably the $50M First Response Fund for Bundibugyo), while CEPI funds push R&D; they jointly run COVAX and share the 100 Days Mission mandate.
• UNICEF Supply Division: UNICEF is CEPI's procurement and delivery counterpart within COVAX, handling vaccine purchase, freight and last-mile delivery to LMICs. The two organizations share the same end-customer (LMIC populations) and operate jointly on outbreak response.
• International AIDS Vaccine Initiative (IAVI): IAVI is a non-profit product development partnership focused on vaccines and antibodies for infectious diseases. It is a direct peer to CEPI as a funder-developer, and is itself a CEPI grantee (rVSV Bundibugyo) — illustrating how CEPI partners sit both alongside and within its ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/cepivaccines
• Facebookfacebook.com/profile.php?id=61551676765636
• LinkedInuk.linkedin.com/company/cepivaccines

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments43 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coalition for Epidemic Preparedness Innovations